Genmab (GMAB) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
26 Oct, 2026Opening remarks and agenda
Chair Deirdre P. Connelly reported on activities during the past year; CEO Jan van de Winkel presented plans for 2024.
CFO Anthony Pagano presented the 2023 Annual Report, endorsed by outgoing auditor PricewaterhouseCoopers.
Financial performance review
The 2023 Annual Report was approved; DKK 4,352 million in annual profit was transferred to retained earnings.
Board and executive committee updates
Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Paolo Paoletti, Anders Gersel Pedersen and Elizabeth O'Farrell were re-elected to the board for one-year terms.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genmab
- DKK 2,166 million of 2019 profit was retained as key AGM resolutions passed.GMAB
AGM 2020 - FY2020 results approved; directors re-elected and governance, remuneration and capital proposals passed.GMABAGM 2021
- FY2021 accounts approved, DKK 3,008 million retained, and one new director elected.GMABAGM 2022
- AGM approved the 2022 accounts and adopted board, remuneration and treasury-share proposals.GMABAGM 2023
- Rina-S significantly improved PFS and OS in Phase 3 platinum-resistant ovarian cancer trial.GMABStudy result
- AbbVie collaboration pairs three bispecific programs with up to four discovery candidates.GMABCollaboration
- Proposed 2026 board pay combines cash fees, RSUs and committee meeting payments.GMABEGM 2026 presentation
- Pivotal phase III oncology readouts in Q4 2026 set up three major launches in 2027.GMABBank of America Global Healthcare Conference
- Rina-S® showed durable activity in gynecologic cancers, advancing toward Phase 3.GMABR&D Update